Hand holding the newspaper resting on a table with a cup of coffee

Newsroom

Taxonomy Icon
StacheStrong Raises $340,000 for the Ivy Brain Tumor Center’s Innovative Phase 0 Clinical Trial of Sonodynamic Therapy for Patients with Glioblastoma
  • December 1, 2021
StacheStrong, a non-profit devoted to raising funds and awareness for brain cancer research, announced they raised $340,000 for the Ivy Brain Tumor Center at Barrow Neurological Institute.
Taxonomy Icon
GlaxoSmithKline Starts Brain Cancer Trials With Key Drug Zejula
  • November 2, 2021
GlaxoSmithKline Plc is partnering with the Ivy Brain Tumor Center to test one of its key oncology medicines against brain cancer as the British pharmaceutical giant looks to expand the drug’s use.
Taxonomy Icon
Ivy Brain Tumor Center Collaborates with GSK on New Phase 0 Clinical Trial to Evaluate Niraparib in Patients with Brain Cancer
  • November 2, 2021
The Ivy Center in collaboration with UCSF Department of Neurological Surgery is pleased to announce a new clinical trial of GSK’s niraparib (ZEJULA) – an FDA-approved drug to treat ovarian cancer – for patients with newly diagnosed glioblastoma and recurrent high-grade gliomas.
Taxonomy Icon
Ivy Brain Tumor Center and SonALAsense Announce Positive Initial Results of the First-in-Human Phase 0/1 Clinical Trial of Non-Invasive Sonodynamic Therapy for Recurrent Glioblastoma
  • September 20, 2021
The Ivy Brain Tumor Center's clinical trial of sonodynamic therapy provides proof of concept for this new metabolically targeted, rapidly acting technology platform for brain tumors
Taxonomy Icon
Ivy Brain Tumor Center Announces Results from Phase 0/1 Clinical Trial of Ribociclib Plus Everolimus in Recurrent High-Grade Glioma
  • September 9, 2021
Published in the journal of Neuro-Oncology and presented at the European Association of Neuro-Oncology, the Ivy Brain Tumor Center announced results from their Phase 0/1 clinical trial of ribociclib plus everolimus in patients with high-grade glioma (HGG).
Taxonomy Icon
Brain tumor research HQ to be built on St. Joseph’s Phoenix campus
  • July 29, 2021
  • Source: Phoenix Business Journal
The Ivy Brain Tumor Center at Barrow Neurological Institute plans to build its 75,000-square-foot global headquarters on the campus of St. Joseph’s Hospital and Medical Center in Phoenix.
Taxonomy Icon
Ivy Brain Tumor Center Announces Plan to Build New Global Headquarters in Phoenix
  • July 21, 2021
The Ivy Brain Tumor Center at Barrow Neurological Institute, the largest Phase 0 clinical trials program for aggressive brain tumors, announced its plans for a new 75,000-square-foot headquarters, with construction beginning in August. The five-story building will be the largest translational research center dedicated to brain tumor drug development in the world.
Taxonomy Icon
Ivy Brain Tumor Center Announces Interim Results from a Phase 0 ‘Trigger’ Trial of Targeted Combination Therapy for Glioblastoma
  • June 4, 2021
The Ivy Brain Tumor Center has announced initial results from an ongoing, dual-drug Phase 0 study evaluating the tumor pharmacokinetics (PK) and tumor pharmacodynamics (PD) of abemaciclib, a selective CDK4/6-inhibitor, plus LY3214996, a selective ERK1/2 inhibitor, in recurrent glioblastoma patients.
Taxonomy Icon
After successful brain tumor surgery Warrington mom prepares for phase two of her journey
  • June 2, 2021
  • Source: Warrington Worldwide
Warrington mother of two Louise Hulme, who flew to America for life-saving surgery to remove a stage four brain tumor, is now preparing for phase two of her journey.
Taxonomy Icon
Valley yoga studio raises awareness for brain tumor research
  • May 23, 2021
  • Source: Fox10 News
Last year, while serving on the frontlines against COVID-19, Ian Youngblood was diagnosed with glioblastoma. Now, Ian is back in Arizona and doing what he loves which includes teaching yoga classes, hiking and motivating everyone around him. On Saturday, May 29, Ian led a charity class in Scottsdale, AZ to support the cutting-edge research happening at the Ivy Brain Tumor Center.